Amgen vs Johnson & Johnson: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: Amgen and Johnson & Johnson side by side

1. 1886Johnson & Johnson

   Johnson & Johnson Founded

   Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson found the company in New Brunswick, New Jersey, with 14 employees, to mass-produce sterile surgical dressings after Robert was inspired by antiseptic pioneer Joseph Lister's 1885 warnings about i…

2. 1920Johnson & Johnson

   Band-Aid Brand Adhesive Bandages Introduced

   J&J introduces the first mass-produced adhesive bandage, sold under the Band-Aid brand starting in 1921; it becomes one of the most recognized consumer-health brands in the world before J&J later spins its consumer division out as Kenvue in 2023.

3. 1943Johnson & Johnson

   Robert Wood Johnson II Writes 'Our Credo'

   Chairman Robert Wood Johnson II authors 'Our Credo,' a one-page statement ranking the company's responsibilities to customers, employees, communities, and shareholders in that order; it remains J&J's official governing philosophy and was later cited as the bas…

4. 1944Johnson & Johnson

   J&J Goes Public

   Johnson & Johnson lists publicly, becoming an independent, market-traded company as it expands into a diversified healthcare business under Chairman Robert Wood Johnson II.

5. 1980Amgen

   Applied Molecular Genetics is incorporated

   Applied Molecular Genetics (AMGen) was incorporated on April 8, 1980 in Thousand Oaks, California, as the idea of venture capitalist William K. Bowes Jr. and a group of scientific collaborators.

6. 1982Johnson & Johnson

   Tylenol Cyanide Poisonings and Nationwide Recall

   After seven people in the Chicago area die from cyanide-laced Extra-Strength Tylenol capsules, J&J issues a nationwide recall of 31 million bottles within a week -- far beyond what investigators said was necessary -- citing Our Credo's customer-safety priority…

7. 1983Amgen

   Nasdaq listing and the erythropoietin clone

   Amgen completed its initial public offering on June 17, 1983, raising nearly US$40 million under chief financial officer Gordon Binder, and formally shortened its name to Amgen.

8. 1984Amgen

   Kirin-Amgen joint venture formed

   Amgen and Kirin Brewery Company of Japan formed Kirin-Amgen in 1984 as a joint venture for the worldwide commercialization of erythropoietin.

9. 1985Amgen

   G-CSF cloned, leading to Neupogen

   While Fu-Kuen Lin's team worked on erythropoietin, researcher Larry Souza and his group cloned and expressed human granulocyte colony-stimulating factor in 1985.

10. 1989Amgen

    FDA approves Epogen

    The FDA approved Epogen (epoetin alfa) on June 1, 1989 for anemia in patients with chronic kidney failure on dialysis. It was the first commercial recombinant human erythropoietin. Epogen's U.S.

11. 1991Amgen

    Neupogen approved, giving Amgen a second franchise

    The FDA approved Neupogen (filgrastim) in February 1991. By stimulating white blood cell production it reduced the risk of infection in cancer patients with chemotherapy-induced neutropenia.

12. 1991Amgen

    Amgen wins the erythropoietin patent fight

    On March 6, 1991 the U.S. Court of Appeals for the Federal Circuit upheld the Kirin-Amgen erythropoietin patent and ruled against Genetics Institute in Amgen v. Chugai Pharmaceutical and Genetics Institute.

13. 2001Amgen

    FDA approves Aranesp, the longer-acting EPO

    Aranesp (darbepoetin alfa), an erythropoietin analogue with modified glycosylation and a longer half-life, was approved in 2001. Less frequent dosing than Epogen improved convenience and gave Amgen a newer, higher-priced product to migrate patients toward.

14. 2002Amgen

    US$16 billion Immunex acquisition brings Enbrel in-house

    Amgen completed its acquisition of Immunex Corporation on July 16, 2002, the largest biotechnology deal to that point at about US$16 billion in stock and cash.

15. 2010Amgen

    Prolia and XGEVA create the bone health franchise

    The FDA approved Prolia (denosumab) for postmenopausal osteoporosis in June 2010 and XGEVA, the same molecule at a higher dose, for prevention of skeletal-related events in cancer patients in November 2010.

16. 2012Johnson & Johnson

    Alex Gorsky Becomes CEO

    Gorsky succeeds William Weldon as CEO amid a period of manufacturing-quality recalls, and spends the next decade restoring J&J's operational reputation while expanding the pharmaceutical and MedTech businesses and developing a single-dose COVID-19 vaccine duri…

17. 2019Amgen

    US$13.4 billion purchase of Otezla from Celgene

    Amgen agreed in August 2019 to buy worldwide rights to Otezla (apremilast) from Celgene for US$13.4 billion in cash, or about US$11.2 billion net of the present value of US$2.2 billion of anticipated future cash tax benefits, and closed on November 21, 2019.

18. 2020Amgen

    Amgen joins the Dow Jones Industrial Average

    Amgen replaced Pfizer in the Dow Jones Industrial Average on August 31, 2020, becoming one of the thirty components in the index. Inclusion recognized the scale Amgen had reached and added passive demand from Dow-tracking funds.

19. 2022Johnson & Johnson

    Joaquin Duato Becomes CEO

    Duato becomes CEO in January 2022, later adding the chairman title, and begins preparing the separation of J&J's consumer-health business from its medicine and device operations.

20. 2023Amgen

    US$27.8 billion Horizon Therapeutics acquisition closes

    Amgen completed the acquisition of Horizon Therapeutics plc on October 6, 2023 for US$116.50 per share in cash, an equity value of about US$27.8 billion, after settling FTC litigation with a behavioral consent decree.

21. 2023Johnson & Johnson

    Kenvue Separation

    J&J completes the spinoff of its consumer-health business (Band-Aid, Tylenol, Listerine, Neutrogena) as the standalone public company Kenvue, narrowing J&J around its higher-margin Innovative Medicine and MedTech segments.

22. 2024Amgen

    Imdelltra becomes the first T-cell engager for small cell lung cancer

    The FDA granted accelerated approval to tarlatamab, sold as Imdelltra, on May 16, 2024 for extensive stage small cell lung cancer that has progressed on or after platinum-based chemotherapy.

23. 2025Amgen

    VESALIUS-CV extends the Repatha case to primary prevention

    In November 2025 Amgen reported Phase 3 VESALIUS-CV results in more than 12,000 patients with atherosclerosis or diabetes but no prior heart attack or stroke.

24. 2025Johnson & Johnson

    FY2025 Sales of $94.193B

    Johnson & Johnson reports $94.193 billion in sales and $26.804 billion in net earnings, split roughly 64% Innovative Medicine and 36% MedTech, both segments growing about 6% year over year.

25. 2025Johnson & Johnson

    Orthopaedics Separation Announced

    In October 2025 J&J announced plans to separate its orthopaedics business as a standalone company operating as DePuy Synthes, targeting completion in 2027.

26. 2026Amgen

    Medicare price setting reaches Enbrel and Otezla

    Enbrel's negotiated Medicare price under the Inflation Reduction Act took effect on January 1, 2026, after it was named in the first round of ten drugs selected for negotiation.

27. 2026Johnson & Johnson

    Proposed Talc Resolution and Raised Guidance

    J&J raised 2026 sales guidance to about $101.1 billion after Q2 sales of $25.31 billion, and on July 27, 2026 proposed an estimated $5.5 billion resolution of remaining ovarian talc claims.

Acquisitions

Questions about Amgen vs Johnson & Johnson